CN103874696B - 作为激酶抑制剂的喹唑啉衍生物及其使用方法 - Google Patents

作为激酶抑制剂的喹唑啉衍生物及其使用方法 Download PDF

Info

Publication number
CN103874696B
CN103874696B CN201280049954.0A CN201280049954A CN103874696B CN 103874696 B CN103874696 B CN 103874696B CN 201280049954 A CN201280049954 A CN 201280049954A CN 103874696 B CN103874696 B CN 103874696B
Authority
CN
China
Prior art keywords
compound
base
amino
piperidin
acid amides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280049954.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103874696A (zh
Inventor
张大为
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Taolue Biotechnology Co Ltd
Original Assignee
TELIGENE Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TELIGENE Ltd filed Critical TELIGENE Ltd
Publication of CN103874696A publication Critical patent/CN103874696A/zh
Application granted granted Critical
Publication of CN103874696B publication Critical patent/CN103874696B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201280049954.0A 2011-10-12 2012-10-12 作为激酶抑制剂的喹唑啉衍生物及其使用方法 Active CN103874696B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161627359P 2011-10-12 2011-10-12
US61/627,359 2011-10-12
PCT/CN2012/001371 WO2013053206A1 (en) 2011-10-12 2012-10-12 Quinazoline derivatives as kinases inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
CN103874696A CN103874696A (zh) 2014-06-18
CN103874696B true CN103874696B (zh) 2015-06-03

Family

ID=48081378

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280049954.0A Active CN103874696B (zh) 2011-10-12 2012-10-12 作为激酶抑制剂的喹唑啉衍生物及其使用方法

Country Status (6)

Country Link
US (1) US9388160B2 (enExample)
EP (1) EP2766356B1 (enExample)
JP (1) JP2014532063A (enExample)
KR (1) KR20140093223A (enExample)
CN (1) CN103874696B (enExample)
WO (1) WO2013053206A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173254A1 (en) * 2012-05-14 2013-11-21 Dawei Zhang Bicyclic compounds as kinases inhibitors
CN104119350B (zh) 2013-04-28 2017-04-12 广东东阳光药业有限公司 氨基喹唑啉类衍生物及其盐和使用方法
WO2016023217A1 (zh) 2014-08-15 2016-02-18 安润医药科技（苏州）有限公司 喹唑啉衍生物、其制备方法、药物组合物和应用
JP2019504830A (ja) * 2016-01-06 2019-02-21 トリリアム・セラピューティクス・インコーポレイテッドＴｒｉｌｌｉｕｍ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Ｅｇｆｒ阻害剤としての新規フッ素化キナゾリン誘導体
AU2019287750A1 (en) * 2018-06-14 2020-10-15 Dana-Farber Cancer Institute, Inc. Cyano quinoline amide compounds as HER2 inhibitors and methods of use
KR102260995B1 (ko) * 2018-11-28 2021-06-04 국립암센터 Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089439A1 (de) * 2002-04-19 2003-10-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, ihre verwendung und verfahren zu ihrer herstellung
CN1751033A (zh) * 2003-02-20 2006-03-22 贝林格尔·英格海姆国际有限公司 双环杂环类,含所述化合物的药物制剂，其用途及制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077104A1 (de) 2000-04-08 2001-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US20040044014A1 (en) 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
PE20040945A1 (es) 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
SI1746999T1 (sl) * 2004-05-06 2012-01-31 Warner Lambert Co 4-fenilamino-kinazolin-6-il-amidi
US7905352B2 (en) * 2004-12-06 2011-03-15 Washington Biotech Corporation Kits containing medicine injection devices and containers
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
CN101100466B (zh) * 2006-07-05 2013-12-25 天津和美生物技术有限公司 不可逆蛋白质酪氨酸磷酰化酶抑制剂及其制备和应用
US8198301B2 (en) 2006-07-05 2012-06-12 Hesheng Zhang Quinazoline and quinoline derivatives as irreversibe protein tyrosine kinase inhibitors
AU2008347940A1 (en) * 2008-01-18 2009-07-23 Natco Pharma Limited 6,7-dialkoxy quinazoline derivatives useful for treatment of cancer related disorders
WO2013166952A1 (en) * 2012-05-07 2013-11-14 Teligene Ltd Substituted aminoquinazolines useful as kinases inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089439A1 (de) * 2002-04-19 2003-10-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, ihre verwendung und verfahren zu ihrer herstellung
CN1751033A (zh) * 2003-02-20 2006-03-22 贝林格尔·英格海姆国际有限公司 双环杂环类,含所述化合物的药物制剂，其用途及制备方法

Also Published As

Publication number Publication date
US20140235658A1 (en) 2014-08-21
WO2013053206A1 (en) 2013-04-18
CN103874696A (zh) 2014-06-18
EP2766356A1 (en) 2014-08-20
KR20140093223A (ko) 2014-07-25
EP2766356A4 (en) 2015-03-25
EP2766356B1 (en) 2018-08-01
US9388160B2 (en) 2016-07-12
JP2014532063A (ja) 2014-12-04

Similar Documents

Publication Publication Date Title
CN104203242B (zh) 取代的喹啉类作为布鲁顿酪氨酸激酶抑制剂
CN105408334B (zh) 作为激酶抑制剂的取代的吡唑并嘧啶类化合物
CN104350049B (zh) 作为激酶抑制剂的取代氨基喹唑啉
CN103874696B (zh) 作为激酶抑制剂的喹唑啉衍生物及其使用方法
EP3181553B1 (en) Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof
EP3102571B1 (en) Substituted pyrimidines useful as egfr-t790m kinase inhibitors
WO2013173254A1 (en) Bicyclic compounds as kinases inhibitors
WO2013041038A1 (en) Pyridine compounds as inhibitors of kinase
JP6609308B2 (ja) キナーゼ阻害剤としての置換マクロサイクル
WO2016026423A1 (en) Substituted macrocycles useful as kinases inhibitors and methods of use thereof
EP3844166A1 (en) Substituted macrocycles useful as kinase inhibitors
US11427559B2 (en) Substituted quinolines useful as kinase inhibitors
JPWO2018159613A1 (ja) ピラゾロ［３，４−ｄ］ピリミジン化合物を用いた抗腫瘍効果増強剤
JP7154455B2 (ja) Ｅｇｆｒ及びｅｒｂｂ２に作用するピリミジン系化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
PP01 Preservation of patent right
PP01 Preservation of patent right

Effective date of registration: 20190613

Granted publication date: 20150603

PD01 Discharge of preservation of patent
PD01 Discharge of preservation of patent

Date of cancellation: 20190816

Granted publication date: 20150603

CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 215123 unit 416, building A4, bio nano Park, 218 Xinghu street, industrial park, Suzhou, Jiangsu

Patentee after: Suzhou Taolue Biotechnology Co., Ltd

Address before: 215123 d33, floor 2, North Block A1, 218 Xinghu street, industrial park, Suzhou, Jiangsu

Patentee before: Suzhou Taolue Biotechnology Co., Ltd